ATRA vs. AUTL

Last updated Apr 1, 2026

Compare and contrast key facts about Atara Biotherapeutics, Inc. (ATRA) and Autolus Therapeutics plc (AUTL).

Performance

ATRA vs. AUTL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atara Biotherapeutics, Inc. (ATRA) and Autolus Therapeutics plc (AUTL). The values are adjusted to include any dividend payments, if applicable.

ATRA vs. AUTL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
ATRA Atara Biotherapeutics, Inc.	-73.85%	35.91%	3.82%	-84.37%	-79.19%	-19.71%	19.19%	-52.59%	-17.78%
AUTL Autolus Therapeutics plc	-30.65%	-15.32%	-63.51%	238.95%	-63.39%	-41.95%	-32.27%	-59.81%	31.36%

Fundamentals

EPS ATRA : $2.54 AUTL : -$0.84
PS Ratio ATRA : 0.50 AUTL : 7.18
Total Revenue (TTM) ATRA : $120.77M AUTL : $51.13M
Gross Profit (TTM) ATRA : $99.56M AUTL : -$158.22M
EBITDA (TTM) ATRA : $40.56M AUTL : -$250.91M

Returns By Period

In the year-to-date period, ATRA achieves a -73.85% return, which is significantly lower than AUTL's -30.65% return.

ATRA

• 1D: 9.49%
• 1M: -12.73%
• YTD: -73.85%
• 6M: -66.99%
• 1Y: -20.37%
• 3Y*: -59.74%
• 5Y*: -58.25%
• 10Y*: -37.23%

AUTL

• 1D: 8.66%
• 1M: -19.30%
• YTD: -30.65%
• 6M: -15.34%
• 1Y: -10.97%
• 3Y*: -9.14%
• 5Y*: -25.24%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ATRA vs. AUTL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATRA

ATRA Risk / Return Rank: 36
ATRA Sharpe Ratio Rank: 33
ATRA Sortino Ratio Rank: 44
ATRA Omega Ratio Rank: 47
ATRA Calmar Ratio Rank: 30
ATRA Martin Ratio Rank: 28

AUTL

AUTL Risk / Return Rank: 36
AUTL Sharpe Ratio Rank: 35
AUTL Sortino Ratio Rank: 40
AUTL Omega Ratio Rank: 38
AUTL Calmar Ratio Rank: 32
AUTL Martin Ratio Rank: 34

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATRA vs. AUTL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Atara Biotherapeutics, Inc. (ATRA) and Autolus Therapeutics plc (AUTL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ATRA	AUTL	Difference
Sharpe ratio Return per unit of total volatility	-0.19	-0.13	-0.05
Sortino ratio Return per unit of downside risk	0.58	0.41	+0.17
Omega ratio Gain probability vs. loss probability	1.09	1.05	+0.05
Calmar ratio Return relative to maximum drawdown	-0.36	-0.31	-0.05
Martin ratio Return relative to average drawdown	-0.79	-0.48	-0.31
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ATRA vs. AUTL - Sharpe Ratio Comparison

The current ATRA Sharpe Ratio is -0.19, which is lower than the AUTL Sharpe Ratio of -0.13. The chart below compares the historical Sharpe Ratios of ATRA and AUTL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ATRA	AUTL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.19	-0.13	-0.05
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.51	-0.32	-0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.39	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.31	-0.39	+0.08

Correlation

The correlation between ATRA and AUTL is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ATRA vs. AUTL - Dividend Comparison

Neither ATRA nor AUTL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ATRA vs. AUTL - Drawdown Comparison

The maximum ATRA drawdown since its inception was -99.74%, roughly equal to the maximum AUTL drawdown of -97.63%. Use the drawdown chart below to compare losses from any high point for ATRA and AUTL.

Drawdown Indicators

	ATRA	AUTL	Difference
Max Drawdown Largest peak-to-trough decline	-99.74%	-97.63%	-2.11%
Max Drawdown (1Y) Largest decline over 1 year	-76.89%	-54.85%	-22.04%
Max Drawdown (5Y) Largest decline over 5 years	-99.16%	-85.68%	-13.48%
Max Drawdown (10Y) Largest decline over 10 years	-99.68%	—	—
Current Drawdown Current decline from peak	-99.70%	-97.13%	-2.57%
Average Drawdown Average peak-to-trough decline	-73.60%	-80.90%	+7.30%
Ulcer Index Depth and duration of drawdowns from previous peaks	34.94%	35.18%	-0.24%

Volatility

ATRA vs. AUTL - Volatility Comparison

Atara Biotherapeutics, Inc. (ATRA) has a higher volatility of 38.92% compared to Autolus Therapeutics plc (AUTL) at 21.17%. This indicates that ATRA's price experiences larger fluctuations and is considered to be riskier than AUTL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ATRA	AUTL	Difference
Volatility (1M) Calculated over the trailing 1-month period	38.92%	21.17%	+17.75%
Volatility (6M) Calculated over the trailing 6-month period	115.23%	56.49%	+58.74%
Volatility (1Y) Calculated over the trailing 1-year period	110.45%	82.98%	+27.47%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	113.89%	79.19%	+34.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	95.60%	81.05%	+14.55%

Financials